{
    "ticker": "IMAR",
    "name": "Imara Inc.",
    "description": "Imara Inc. is a biotechnology company focused on developing innovative therapies for patients with rare hematologic diseases. Founded in 2015, Imara is dedicated to addressing unmet medical needs through its proprietary drug discovery platform and advanced clinical development programs. The company is primarily engaged in the research and development of treatments for sickle cell disease and beta-thalassemia, utilizing its expertise in gene therapy and molecular biology. Imara's lead product candidate, IMR-687, is designed to enhance the production of fetal hemoglobin, aiming to improve the health and quality of life for patients suffering from these debilitating conditions. The company is committed to advancing its pipeline through rigorous clinical trials and collaborations with leading research institutions. Imara's mission is to transform the treatment landscape for patients with rare blood disorders, enhancing their lives through effective and safe therapeutic options, while also striving to become a leader in the field of hematology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Boston, Massachusetts, USA",
    "founded": "2015",
    "website": "https://www.imarainc.com",
    "ceo": "Dr. Aisling M. Burnand",
    "social_media": {
        "twitter": "https://twitter.com/ImaraInc",
        "linkedin": "https://www.linkedin.com/company/imara-inc/"
    },
    "investor_relations": "https://www.imarainc.com/investors",
    "key_executives": [
        {
            "name": "Dr. Aisling M. Burnand",
            "position": "CEO"
        },
        {
            "name": "Dr. David A. E. M. Baker",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "IMR-687"
            ]
        }
    ],
    "seo": {
        "meta_title": "Imara Inc. | Innovative Therapies for Rare Hematologic Diseases",
        "meta_description": "Explore Imara Inc., a biotechnology company focused on developing novel treatments for sickle cell disease and beta-thalassemia. Learn about our mission and research.",
        "keywords": [
            "Imara",
            "Biotechnology",
            "Sickle Cell Disease",
            "Beta-Thalassemia",
            "IMR-687",
            "Rare Diseases"
        ]
    },
    "faq": [
        {
            "question": "What does Imara Inc. do?",
            "answer": "Imara Inc. develops innovative therapies for rare hematologic diseases such as sickle cell disease and beta-thalassemia."
        },
        {
            "question": "Who is the CEO of Imara?",
            "answer": "Dr. Aisling M. Burnand is the CEO of Imara Inc."
        },
        {
            "question": "Where is Imara headquartered?",
            "answer": "Imara is headquartered in Boston, Massachusetts, USA."
        },
        {
            "question": "What is Imara's lead product candidate?",
            "answer": "Imara's lead product candidate is IMR-687, aimed at treating sickle cell disease."
        },
        {
            "question": "When was Imara founded?",
            "answer": "Imara was founded in 2015."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "SGMO",
        "VRTX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "REGN"
    ]
}